Neion Bio, a biotech start-up founded in 2024, has emerged from stealth mode with plans to revolutionize pharmaceutical manufacturing by turning chicken eggs into drug factories. The company announced a partnership with a major pharmaceutical company to develop three compounds using genetically engineered birds that produce medical proteins in their egg whites.

Scientists have pursued egg-based drug production for three decades with limited success - only one FDA-approved chicken-produced drug exists today. Kanuma, a treatment for a rare liver disorder, costs patients $310,000 annually. However, recent advances in chicken genetic engineering have made the process far more reliable. Researchers can now manipulate primordial germ cells with precision, allowing for consistent drug production.

The economic implications are substantial. Manufacturing drugs using Chinese hamster ovary cells requires billion-dollar facilities and complex maintenance. By contrast, Neion Bio estimates that producing the arthritis drug Humira would require just 3,900 hens at one-hundredth the cost of traditional methods. As co-founder Sam Levin notes, 'It's a medical supply chain that runs on grain and water.'